Furthermore, as RAD51D is involved in DNA repair through homologous recombination (HR), it is possible that carcinomas arising in patients carrying RAD51D mutations will be sensitive to chemotherapeutic agents that target this pathway, such as cisplatin and the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, as demonstrated in BRCA1/2 mutation-carrier cancer patients (Banerjee et al, 2010; Loveday et al, 2011). Here, RAD51D is linked to carcinoma.